Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.
This month, MD Anderson finalized an asset purchase agreement with Bellicum...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...
Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes (TIL) and endogenous T cells (ETC) have demonstrated promise for treating cancer. Based on these advances, MD Anderson and Berkeley Lights Inc. have announced the launch of Optera Therapeutics Corp, a biopharmaceutical company that will develop cell therapies to treat patients with their own immune...
